FDA Cites Hawaii PET Drugmaker for Quality Violations

Drug Industry Daily
A A
Issues ranging from unqualified personnel to inadequate recordkeeping netted Honolulu, Hawaii-based positron emission tomography (PET) drugmaker Hamamatsu/Queens PET Imaging Center a Form 483 from the FDA.

To View This Article:

Login

Subscribe To Drug Industry Daily